Page 1

RNS Number : 3979R Shield Therapeutics PLC 20 August 2026 Shield Therapeutics plc ( " Shield " or the " Company " or the " Group " ) Interim results for the six months ended 30 June 2026 H1 revenues of $ 30.4M with strong growth in the commercially insured patients ' segment On track for operating profitability in 2026 c . 102,000 ACCRUFER® prescriptions sold , up from c.84,000 in H1 2025 London , UK , August 20 , 2026 : Shield Therapeutics plc ( LSE : STX ) , a commercial - stage pharmaceutical company specialising in iron deficiency , announces the release of its unaudited interim results for the six months ended 30 June 2026 and confirms that the Company remains on track for operating profitability in 2026 . Financial Highlights H1 2026 Group revenues : $ 30.4 million , increasing 42 % over H1 2025 ( $ 21.4 million ) O ACCRUFERⓇ revenue : $ 20.1 million , increasing 5 % over H1 2025 ( $ 19.2 million ) o Ex - US revenue : $ 10.3 million in milestones and royalties from global partners in China , Europe , Canada and Japan ( H1 2025 : $ 2.2 million ) Group loss significantly narrowed : $ 2.3 million loss compared to $ 9.5 million loss in H1 2025 driven primarily by higher Group revenues alongside continuance of streamlining business expenditures Cash and cash equivalents : $ 8.3 million ( 31 December 2025 : $ 11.6 million ) Operational Highlights H1 2026 • Commercialisation of ACCRUFER® in the US : Continued growth and strong market results : ACCRUFER® total prescriptions grew to c.102,000 in H1 2026 , up from c.84,000 in H1 2025 , an increase of 21 % . The growth was achieved despite changes to Prior Authorisation ( PA ) requirements for prescription approvals in the Medicaid programme in New York , retaining only c.5 % of approved prescriptions from May , to which the Company responded by pivoting focus to commercially insured patients . The prescription growth in this segment during the same period was 27 % . ACCRUFER® average net selling price in H1 2026 was $ 199 ( H1 2025 : $ 214 ) , in part reflecting the changes in New York's Medicaid programme referenced above . Global ACCRUFERⓇ / FeRACCRUⓇ development programs saw continued progress in commercial and development stage partnerships in Canada , Japan , China , Europe / UK and the US and EU pediatric indication extensions : O MEDLEAP Pharma ( a subsidiary of Vital KSK Holdings Inc. , operating under Shield's exclusive licence with VITAL - NET , Inc. ) in Japan : MEDLEAP confirmed first patient enrolment in a Phase II clinical trial of ACCRUFER® ( ferric maltol ) for Pulmonary Arterial Hypertension ( PAH ) in Japan , an exploratory study intended to support a planned Phase III trial . This follows confirmation by Japan's Pharmaceuticals and Medical Devices Agency ( PMDA ) of the development plan for ACCRUFERⓇ as a PAH treatment , based on the drug's prior clinical results from trials in Europe , the UK and the US . 0 ASK Pharma ( " ASK " ) in China : In H1 2026 , the Company recognised a $ 7.9 million development milestone payment from ASK ( H1 2025 : $ nil ) , a key driver of the increase in ex - US revenue for the period . o Pediatric indication extensions : Following the positive Phase III pediatric clinical trial ( FORTIS / ST10-01-305 ) , the Company has secured pediatric indication extensions in its key markets . In the US , approval for patients 10 years of age and older was received on 1 April 2026. In Europe , the European Medicines Agency ( EMA ) issued a positive opinion on 26 March 2026 , followed by the European Commission's ( EC ) decision on 26 May 2026 , extending the indication to patients 12 years of age and older ; the UK's Medicines and Healthcare products Regulatory Agency ( MHRA ) approved the same extension on 2 July 2026 . Anders Lundstrom , CEO of Shield Therapeutics , commented : " We are pleased with our H1 2026 results showing growth in revenue and prescriptions over Q1 2026 , despite the Medicaid changes in New York . Since May , we have retained roughly 5 % of NY Medicaid - approved prescriptions . The adaptability of our sales force is especially encouraging given how quickly we pivoted to commercially insured patients , our largest segment , at two - thirds of total revenue which grew 27 % and drove strong overall prescription growth in H1 2026. Our earlier experience in Texas , where we successfully shifted from Medicaid to commercially insured patients , gives us continued confidence in applying the same strategy in New York and in sustaining ACCRUFER®'s growth . In the US , we are also excited about our first GPO contract , which opens access to over 400 additional clinics , and our newly launched pediatric indication . Globally , we continue to make good progress : pediatric extensions in Europe , strong growth in Canada and the UK , and 2027 targets launch in both China and Korea .